Antifungal strategies for managing invasive aspergillosis: The prospects for a pre-emptive treatment strategy

References

• Herbrecht R, Neuville S, Letscher-Bru V, et al. Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment. Drugs Aging 2000; 17: 339–351
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475–482
   PubMed Web of Science ®Google Scholar
• Thursky K, Byrnes G, Grigg A, et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 115–121
   PubMed Web of Science ®Google Scholar
• Baddley JW, Stroud TP, Salzman D, et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319–1324
   PubMed Web of Science ®Google Scholar
• Grow WB, Moreb JS, Roque D, et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15–19
   PubMed Web of Science ®Google Scholar
• Bow EJ, Loewen R, Cheang MS, et al. Invasive fungal disease in adults undergoing remission induction for acute myeloid leukemia: the pathogenic role of the antileukemic regimen. Clin Infect Dis 1995; 2: 361–369
   Google Scholar
• Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomised, double-blind study. J Infect Dis 1995; 171: 1545–1552
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827–833
   PubMed Web of Science ®Google Scholar
• Gibbs SD, Herbert KE, McCormack C, et al. Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukemia and Sezary syndrome. Eur J Haematol 2004; 73: 447–449
   PubMed Web of Science ®Google Scholar
• Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273–284
   PubMed Web of Science ®Google Scholar
• Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781–803
   PubMed Web of Science ®Google Scholar
• Lin SJ, Schranz J, Theutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001; 32: 358–366
   PubMed Web of Science ®Google Scholar
• Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12: 310–350
   PubMed Web of Science ®Google Scholar
• Jantunen E, Piilonen A, Volin L, et al. Diagnostic aspects of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 2000; 25: 867–871
   PubMed Web of Science ®Google Scholar
• Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100: 171–178
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Habicht J, Matt P, et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant 1999; 24: 1195–1199
   PubMed Web of Science ®Google Scholar
• Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139–147
   PubMed Web of Science ®Google Scholar
• Hauggaard A, Ellis M, Ekelund L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiologica 2002; 43: 292–298
   PubMed Web of Science ®Google Scholar
• von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: Early diagnosis improves survival. Respiration 1995; 62: 341–347
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751
   PubMed Web of Science ®Google Scholar
• Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology (DGHO), study group interventional therapy of unexplained fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82(Suppl 2)S105–S117
   Google Scholar
• Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized placebo-controlled trial. Blood 2000; 96: 2055–2061
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med 2003; 138: 705–713
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527–1533
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematological malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615–4626
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Molitor E, Hahn C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukemia. Leukemia 1998; 12: 1338–1343
   PubMed Web of Science ®Google Scholar
• Glashmacher A, Hahn C, Molitor E, , et al. Definition of a minimal effective trough concentration of itraconazole for antifungal prophylaxis in severely neutropenic patients with hematological malignancies. In Microbiology Asf, ed., Abstracts of 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 26–29 September 1999; A66.
   Google Scholar
• Morgenstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901–911
   PubMed Web of Science ®Google Scholar
• Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with haematological malignancies: a randomized, placebo-controlled, double-blind, multicentre trial. GIMEMA Infection Program. Clin Infect Dis 1999; 28: 250–255
   PubMed Web of Science ®Google Scholar
• Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000; 44: 2310–2318
   PubMed Web of Science ®Google Scholar
• Sable CA, Nguyen B-YT, Chodakewitz JA, et al. Safety and tolerability of caspofungin in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25–30
   PubMedGoogle Scholar
• van Burik J-AH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin infect Dis 2004; 39: 1407–1416
   PubMed Web of Science ®Google Scholar
• Tollemar J, Ringden O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577–582
   PubMed Web of Science ®Google Scholar
• Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin B (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163–168
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, White TC, et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309–316
   PubMed Web of Science ®Google Scholar
• Laverdiere M, Rotstein C, Bow EJ, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 2000; 46: 1001–1008
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225–234
   PubMed Web of Science ®Google Scholar
• Wingard JR. Design issues in a prospective randomized double-blind trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis 2004; 39(Suppl 4)S176–S180
   Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952
   PubMed Web of Science ®Google Scholar
• Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584–587
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fedricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin infect Dis 2004; 39: 743–746
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer centre in the era of Aspergillus-active antifungal therapy: A case-control observational; study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. A multicentre trial of oral posaconazole vs. fluconazole for the prophylaxis of invasive fungal infections in recipients of allogeneic haematopoietic stem cell transplantation with graft-vs.-host-disease. Mycoses 2005; 48(Suppl 2)26a–27a
   Google Scholar
• Cornely O. Posaconazole (POS) vs. standard azoles as prophylaxis in neutropenic patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): Impact on mortality. Abstracts of 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, 16–19 December, 2005, Abstract 722-b.
   Google Scholar
• Bennett JE, Powers J, Walsh T, et al. Forum report: Issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003; 36(Suppl 3)S117–S122
   Web of Science ®Google Scholar
• Bodey GP. Fungal infection and fever of unknown origin in neutropenic patients. Am J Med 1986; 80: 112–119
   PubMed Web of Science ®Google Scholar
• Aisner J, Wiernik PH, Schimpff SC. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 1977; 86: 539–543
   PubMed Web of Science ®Google Scholar
• DeGregorio MW, Lee WM, Linker CA, et al. Fungal infections in patients with acute leukemia. Am J Med 1982; 73: 543–548
   PubMed Web of Science ®Google Scholar
• Holleran WM, Wilbur JR, DeGregorio MW. Empiric amphotericin B therapy in patients with acute leukaemia. Rev Infect Dis 1985; 7: 619–624
   PubMedGoogle Scholar
• Stein RS, Kayser J, Flexner JM. Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer 1982; 50: 2247–2251
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101–111
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668–672.
   PubMed Web of Science ®Google Scholar
• Karp JE, Merz WG, Charache P. Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia. Rev Infect Dis 1991; 13: 592–599
   PubMedGoogle Scholar
• Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711–718
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New Engl J Med 1999; 340: 764–771
   PubMed Web of Science ®Google Scholar
• Winston DJ, Hathorn JW, Schuster MG, et al. A multicentre randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108: 282–289
   PubMed Web of Science ®Google Scholar
• Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001; 135: 412–422
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391–1402
   PubMed Web of Science ®Google Scholar
• Curtis AM, Smith GJW, Ravin CE. Air crescent sign of invasive aspergillosis. Radiology 1979; 133: 17–21
   PubMed Web of Science ®Google Scholar
• Gefter WB, Albelda SM, Talbot GH, et al. Invasive pulmonary aspergillosis and acute leukemia: Limitations in the diagnostic utility of the air-crescent sign. Radiology 1985; 157: 605–610
   PubMed Web of Science ®Google Scholar
• Kuhlman JE, Fishman EK, Burch PA, et al. Invasive pulmonary aspergillosis in acute leukemia: The contribution of CT to early diagnosis and aggressive management. Chest 1987; 92: 95–99
   PubMed Web of Science ®Google Scholar
• Stynen D, Goris A, Sarfati J, et al. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33: 497–500
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223–3228
   PubMed Web of Science ®Google Scholar
• Sulahian A, Boutboul F, Ribaud P, et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001; 91: 311–318
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604–1610
   PubMed Web of Science ®Google Scholar
• Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186: 1297–1306
   PubMed Web of Science ®Google Scholar
• Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34: 939–943
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898–1906
   PubMed Web of Science ®Google Scholar
• Marr K, Gugel A, Balajee A, et al. A multi-centre evaluation of Bio-Rad Aspergillus GM EIA: Data supporting FDA approval of the test using a low cut-off to define positivity. Blood 2003; 102: 970a
   Web of Science ®Google Scholar
• Rovira M, Jimenez M, De La Bellacasa J, et al. Detection of Aspergillus galactomannan by enzyme immunosorbent assay in recipients of allogeneic haematopoietic stem cell transplantation: a prospective study. Transplantation 2004; 77: 1260–1264
   PubMed Web of Science ®Google Scholar
• Pinel C, Fricker-Hidalgo H, Lebeau B, et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003; 41: 2184–2186
   PubMed Web of Science ®Google Scholar
• Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762–1769
   PubMed Web of Science ®Google Scholar
• Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005; 41: S381–S386
   PubMed Web of Science ®Google Scholar
• Siemann M, Koch-Dorfler M, Gaude M. False-positive results in premature infants with the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay. Mycoses 1998; 41: 373–377
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Klont RR, Warris A, et al. Bifdobacterium lipoteichoic acid and false ELSA reactivity in Aspergillus antigen detection. Lancet 2004; 363: 325–327
   PubMed Web of Science ®Google Scholar
• Blijlevens NMA, Donnelly JP, Meis JFGM, et al. Aspergillus galactomannan antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition. Transpl Infect Dis 2002; 4: 64–65
   PubMedGoogle Scholar
• Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan Platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913–916
   PubMed Web of Science ®Google Scholar
• Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349: 2366–2367
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004; 42: 4744–4748
   PubMed Web of Science ®Google Scholar
• Singh N, Obman A, Husain S, et al. Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother 2004; 48: 1989–1902
   PubMed Web of Science ®Google Scholar
• FDA. Practice caution in using Bio-Rad Platelia™ Aspergillus EIA. Available online at, , http://www.fda.gov/cdrh/oivd/laboratory.html#tip8 (accessed on 10 July 2006).
   Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E, et al. β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199–205
   PubMed Web of Science ®Google Scholar
• Obayashi T, Yoshida M, Mori T, et al. Plasma (1→3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17–20
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Alexander B, Kett D, et al. Multicenter clinical evaluation of the (1→3)β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654–659
   PubMed Web of Science ®Google Scholar
• Hayette M-P, Vaira D, Susin F, et al. Detection of Aspergillus species DNA by PCR in bronchoalveolar lavage fluid. J Clin Microbiol 2001; 39: 2338–2340
   PubMed Web of Science ®Google Scholar
• Tang CM, Holden DW, Aufauvre-Brown A, et al. The detection of Aspergillus spp. by the polymerase chain reaction and its evaluation in bronchoalveolar lavage fluid. Am Rev Respir Dis 1993; 148: 1313–1317
   PubMed Web of Science ®Google Scholar
• Costa C, Vidaud D, Olivi M, et al. Development of two real-time quantitative TaqMan PCR assays to detect circulating Aspergillus fumigatus DNA in serum. J Microbiol Methods 2001; 44: 263–269
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Loeffler J, Hebart H, Brauchle U, et al. Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR. J Clin Microbiol 2000; 38: 3830–3833
   PubMed Web of Science ®Google Scholar
• Reiss E, Obayashi T, Orle K, et al. Non-culture-based diagnostic tests for mycotic infections. Med Mycol 2000; 38(Suppl 1)S147–S159
   PubMedGoogle Scholar
• Loeffler J, Hebart H, Sepe S, et al. Detection of PCR-amplified fungal DNA by using a PCR-ELISA system. Med Mycol 1998; 36: 275–279
   PubMed Web of Science ®Google Scholar
• van Burik JA, Myerson D, Schreckhise RW, et al. Panfungal PCR assay for the detection of fungal infection in human blood specimens. J Clin Microbiol 1998; 36: 1169–1175
   PubMed Web of Science ®Google Scholar
• Scott J, Schekman R. Lyticase: endoglucanase and protease activities that act together in yeast cell lysis. J Bacteriol 1980; 142: 414–423
   PubMed Web of Science ®Google Scholar
• Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997; 35: 1353–1360
   PubMed Web of Science ®Google Scholar
• Yamakami Y, Hashimoto A, Yamagata E, et al. Evaluation of PCR for detection of DNA specific for Aspergillus species in sera of patients with various forms of pulmonary aspergillosis. J Clin Microbiol 1998; 36: 3619–3623
   PubMed Web of Science ®Google Scholar
• Loeffler J, Hebart H, Schumacher U, et al. Comparison of different methods for extraction of DNA of fungal pathogens from cultures and blood. J Clin Microbiol 1997; 35: 3311–3312
   PubMed Web of Science ®Google Scholar
• Skladny H, Buchheidt D, Baust C, et al. Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. J Clin Microbiol 1999; 37: 3865–3871
   PubMed Web of Science ®Google Scholar
• Hebart H, Loffler J, Meisner C, et al. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000; 181: 1713–1719
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Aigner J, Gunsilius E, et al. Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol 2001; 113: 180–184
   PubMed Web of Science ®Google Scholar
• Williamson E, Leeming J, Palmer H, et al. Diagnosis of invasive aspergillosis in bone marrow transplant recipients by polymerase chain reaction. Br J Haematol 2000; 108: 132–139
   PubMed Web of Science ®Google Scholar
• Buchheidt D, Baust C, Skladny H, et al. Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step PCR: clinical results. Clin Infect Dis 2001; 33: 428–435
   PubMed Web of Science ®Google Scholar
• Ferns RB, Fletcher H, Bradley S, et al. The prospective evaluation of a nested polymerase chain reaction assay for the early detection of Aspergillus infection in patients with leukaemia or undergoing allograft treatment. Br J Haematol 2002; 119: 720–25
   PubMed Web of Science ®Google Scholar
• Loeffler J, Henke N, Hebart H, et al. Quantification of fungal DNA using fluorescence resonance energy transfer and the Light Cycler system. J Clin Microbiol 2000; 38: 586–590
   PubMed Web of Science ®Google Scholar
• Jones ME, Fox AJ, Barnes AJ, et al. PCR-ELISA for the early diagnosis of invasive pulmonary Aspergillus infection in neutropenic patients. J Clin Pathol 1998; 51: 652–656
   PubMed Web of Science ®Google Scholar
• Jordanides NE, Allan EK, McLintock LA, et al. A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplant 2005; 35: 389–395
   PubMed Web of Science ®Google Scholar
• Halliday C, Hoile R, Sorrell T, et al. Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. Br J Haematol 2006; 132: 478–486
   PubMed Web of Science ®Google Scholar
• Florent M, Katsahian S, Vekhoff A, et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 2006; 193: 741–747
   PubMed Web of Science ®Google Scholar
• White PL, Linton CJ, Perry MD, et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479–486
   PubMed Web of Science ®Google Scholar
• Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230–240
   PubMed Web of Science ®Google Scholar
• Buchheidt D, Hummel M, Schleiermacher D, et al. Prospective clinical evaluation of a LightCycler™-mediated polymerase chain reaction assay, a nested PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 125: 196–202
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Gunsilius E, Gastl G, et al. Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Micro 2004; 42: 4154–4157
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Speth C, Mayr A, et al. Diagnosing and monitoring of invasive aspergillosis during antifungal therapy by polymerase chain reaction: an experimental study in mice. Diag Microbiol Infect Dis 2003; 47: 569–572
   PubMed Web of Science ®Google Scholar
• Spiess B, Buchheidt D, Baust C, et al. Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients. J Clin Microbiol 2003; 41: 1811–1818
   PubMed Web of Science ®Google Scholar
• Halliday C, Wu QX, James G, et al. Development of a nested qualitative PCR assay to detect Aspergillus DNA in clinical specimens. J Clin Microbiol 2005; 43: 5366–5368
   PubMed Web of Science ®Google Scholar
• O'Sullivan C, Kasai M, Francesconi A, et al. Development and validation of a quantitative real-time PCR assay using fluorescence resonance energy transfer technology for detection of Aspergillus fumigatus in experimental invasive pulmonary aspergillosis. J Clin Microbiol 2003; 14: 5676–5682
   Google Scholar
• Sanguinetti M, Posteraro B, Pagano L, et al. Comparison of real-time PCR, conventional PCR and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from haematology patients for diagnosis of Invasive Pulmonary Aspergillosis. J Clin Microbiol 2003; 41: 3922–3925
   PubMed Web of Science ®Google Scholar
• Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 33: 1504–1512
   PubMed Web of Science ®Google Scholar
• Pryce TM, Kay ID, Palladino S, et al. Real-time automated polymerase chain reaction (PCR) to detect Candida albicans and Aspergillus fumigatus DNA in whole blood from high-risk patients. Diag Microbiol Infect Dis 2003; 47: 487–496
   PubMed Web of Science ®Google Scholar
• Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive aspergillosis. Br J Haematol 2003; 121: 448–457
   PubMed Web of Science ®Google Scholar
• Yoo J-H, Choi J-H, Choi S-M, et al. Application of nucleic acid sequence-based amplification for diagnosis of and monitoring the clinical course of invasive aspergillosis in patients with hematological diseases. Clin Infect Dis 2005; 40: 392–398
   PubMed Web of Science ®Google Scholar
• Severens J, Donnelly JP, Meis JFGM, et al. Two strategies for managing invasive aspergillosis: A decision analysis. Clin Infect Dis 1997; 25: 1148–1154
   PubMed Web of Science ®Google Scholar
• Lin M-T, Lu H-S, Chen W-L. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 2001; 33: 1621–1627
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based pre-emptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005; 41: 1242–1250
   PubMed Web of Science ®Google Scholar
• Hebart H, Klingspor L, Klingebiehl T, , et al. PCR-based liposomal amphotericin B treatment following allogeneic stem cell transplantation is a safe treatment strategy: Preliminary results of a prospective study. Blood 2004; 104: 192 abstract #59a.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Morrissey CO, Bradstock, , et al. A multicentre randomised controlled trial comparing two strategies for the diagnosis of invasive aspergillosis in high-risk haematology patients. Available online at, , http://www.clinicaltrials.gov (accessed on 10 July 2006).
   Google Scholar